Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors.
+ 1 more risk
Flawless balance sheet with limited growth.
Share Price & News
How has Crinetics Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CRNX's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: CRNX underperformed the US Biotechs industry which returned 1.6% over the past year.
Return vs Market: CRNX underperformed the US Market which returned -10.7% over the past year.
Price Volatility Vs. Market
How volatile is Crinetics Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StThe Crinetics Pharmaceuticals (NASDAQ:CRNX) Share Price Is Down 12% So Some Shareholders Are Getting Worried
3 months ago | Simply Wall StCrinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans
4 months ago | Simply Wall StDid You Manage To Avoid Crinetics Pharmaceuticals's (NASDAQ:CRNX) 29% Share Price Drop?
Is Crinetics Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate CRNX's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate CRNX's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: CRNX is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: CRNX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CRNX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CRNX is overvalued based on its PB Ratio (2.9x) compared to the US Biotechs industry average (2.6x).
How is Crinetics Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CRNX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CRNX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CRNX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CRNX's revenue (58.3% per year) is forecast to grow faster than the US market (7.2% per year).
High Growth Revenue: CRNX's revenue (58.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CRNX is forecast to be unprofitable in 3 years.
How has Crinetics Pharmaceuticals performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: CRNX is currently unprofitable.
Growing Profit Margin: CRNX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if CRNX's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare CRNX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CRNX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22%).
Return on Equity
High ROE: CRNX has a negative Return on Equity (-43.04%), as it is currently unprofitable.
How is Crinetics Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: CRNX's short term assets ($123.3M) exceed its short term liabilities ($8.3M).
Long Term Liabilities: CRNX's short term assets ($123.3M) exceed its long term liabilities ($4.9M).
Debt to Equity History and Analysis
Debt Level: CRNX is debt free.
Reducing Debt: CRNX had no debt 5 years ago.
Inventory Level: CRNX has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if CRNX's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CRNX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: CRNX has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of -63.4% each year.
What is Crinetics Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CRNX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate CRNX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CRNX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CRNX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CRNX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
R. Struthers (57yo)
Dr. R. Scott Struthers, Ph.D. founded Crinetics Pharmaceuticals, Inc. in 2008 and serves as its Chief Executive Officer and President since December 2008. Prior to Crinetics, Dr. Struthers served as Senior ...
CEO Compensation Analysis
Compensation vs Market: R.'s total compensation ($USD3.04M) is above average for companies of similar size in the US market ($USD2.13M).
Compensation vs Earnings: R.'s compensation has increased whilst the company is unprofitable.
|CFO & Secretary||2.25yrs||US$1.03m||0.24% $792.5k|
|Chief Medical Officer||1.83yrs||US$1.74m||0.020% $66.6k|
|Founder & Vice President of Chemistry||no data||no data||no data|
|Co-Founder & VP of Biology||no data||no data||no data|
Experienced Management: CRNX's management team is considered experienced (2.3 years average tenure).
|Independent Chairman of the Board||4.5yrs||US$60.14k||0.30% $1.0m|
|Independent Director||4.5yrs||US$40.81k||no data|
|Independent Director||2.17yrs||US$82.57k||0.051% $169.0k|
|Member of Scientific Advisory Board||no data||no data||no data|
|Member of Scientific Advisory Board||3.42yrs||no data||no data|
|Independent Director||2.17yrs||US$21.69k||no data|
|Independent Director||0.75yr||no data||no data|
|Member of Scientific Advisory Board||1.17yrs||no data||no data|
Experienced Board: CRNX's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 99.1%.
Crinetics Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Crinetics Pharmaceuticals, Inc.
- Ticker: CRNX
- Exchange: NasdaqGS
- Founded: 2008
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$331.162m
- Shares outstanding: 24.57m
- Website: https://www.crinetics.com
Number of Employees
- Crinetics Pharmaceuticals, Inc.
- Building 2
- 10222 Barnes Canyon Road
- San Diego
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CRNX||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Jul 2018|
|6Z4||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jul 2018|
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly. The company is also developing CRN01941, an oral, selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors; CRN02481, an oral selective nonpeptide somatostatin type 5 receptor agonist used for the treatment of congenital hyperinsulinism; and adrenocorticotrophic hormone antagonist for the treatment of cushing’s diseases. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/02 07:26|
|End of Day Share Price||2020/04/01 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.